What is ECL Cell Hyperplasia in Autoimmune Gastritis?

Seeing “hyperplasia” on a pathology report can be frightening, especially if you look it up and see words like “tumors.” However, ECL cell hyperplasia is not cancer. In the context of autoimmune gastritis, it is simply an overgrowth of a specific type of stomach cell—called enterochromaffin-like (ECL) cells—that happens as a natural consequence of your condition ^[1].

Understanding why this happens can help take the fear out of your biopsy report.

The Domino Effect: Low Acid and High Gastrin

Your stomach contains different types of cells. In autoimmune gastritis, your immune system mistakenly attacks parietal cells ^[2]. These cells do two very important things: they make stomach acid, and they help your body absorb crucial nutrients. (This is why many people with autoimmune gastritis also experience iron or vitamin B12 deficiency anemia).

As these parietal cells are destroyed, your stomach acid levels drop. Your body realizes the acid is too low and tries to fix the problem by producing large amounts of a hormone called gastrin ^[3]. Normally, gastrin tells your stomach to make more acid. But because your acid-making cells are damaged, the acid levels stay low, and your body keeps pumping out more and more gastrin.

Gastrin doesn’t just stimulate acid; it also stimulates your ECL cells. Under the constant signal of high gastrin levels, these ECL cells begin to multiply and grow in number. This overgrowth is what pathologists call hyperplasia ^[4][5].

Is It Cancer?

No. ECL cell hyperplasia is considered a benign (non-cancerous) precursor condition ^[3]. However, because these cells are constantly being stimulated to grow, there is a chance they can eventually form small growths known as Type 1 gastric neuroendocrine tumors (gNETs) ^[6].

The progression happens in slow, predictable steps ^[6]:

• Simple or Linear Hyperplasia: The earliest stage, where ECL cells just start to increase in number ^[2].
• Micronodular Hyperplasia: The cells start forming tiny, microscopic clusters ^[7].
• Dysplasia: The cells begin to look abnormal under a microscope ^[8].
• Type 1 gNET: A small, usually slow-growing tumor forms ^[3].

Even if the hyperplasia eventually turns into a Type 1 gNET, it is crucial to know that Type 1 gNETs are very different from traditional, aggressive stomach cancer (adenocarcinoma). Type 1 gNETs are almost always small, slow-growing, and highly treatable—often by simply removing them during a routine endoscopy, though more advanced cases may require other treatments ^[6].

Why Routine Monitoring Matters

Because ECL cell hyperplasia can slowly progress over time, it is a hallmark sign that you need routine monitoring ^[9]. Your gastroenterologist will likely recommend periodic upper endoscopies to keep a close eye on your stomach lining ^[10][11].

There is generally no medication you need to take to “cure” or reverse ECL cell hyperplasia. Instead, careful surveillance is the standard of care. There is no single universal timeline for how often you need an endoscopy—your doctor will customize a schedule based on your specific biopsy results and risk factors ^[12].

The goal of this surveillance is simple: to monitor the health of your stomach, check for other risks associated with autoimmune gastritis, and catch any cellular changes early so they can be safely managed before they become a problem ^[13][10].